鎮痙薬の世界市場レポート 2025年

鎮痙薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.8％で219億1,000万米ドルに成長します。予測期間の成長は、ヘルスケア支出の増加、個別化医療、世界の人口増加、新興市場、臨床試験、調査に起因しています。予測期間の主な動向としては、抗痙攣薬の適応拡大、ヘルスケアインフラ開発、医薬品開発の進歩、認知度・診断度の向上、非侵襲的治療オプションの選好などが挙げられます。

予想される高齢者人口の増加は、鎮痙薬市場成長の原動力となっています。65歳以上の高齢者は、身体的・精神的に様々な課題を抱えていることが多く、筋肉の痙攣やけいれんの原因となる症状に対処するために鎮痙剤に救いを見出しています。これらの薬は、過敏性腸症候群（IBS）、胃食道逆流症（GERD）、間質性膀胱炎、子宮けいれんなどの疾患にも有効です。2022年10月、世界保健機関（WHO）は、60歳以上の世界人口が大幅に増加し、2030年には14億人に達し、2050年には21億人に倍増すると予測しました。2050年には4億2,600万人に達すると推定される80歳以上の高齢者の大幅な増加を含むこの人口動態の変化は、高齢者人口の拡大が鎮痙薬市場を牽引する原動力となっていることを強調しています。

過敏性腸症候群（IBS）の罹患率の上昇が、今後の鎮痙薬市場の成長を牽引すると予想されます。IBSは、大腸（結腸）に影響を与え、不快感を引き起こし、正常な消化機能を阻害する一連の症状を特徴とする消化器系の疾患です。鎮痙薬はIBSの治療に利用され、胃腸管の筋肉の痙攣やけいれんを標的として緩和し、患者に腹痛や不快感からの解放をもたらします。例えば、2024年6月、米国連邦政府機関である疾病管理予防センター（CDC）は、米国における炎症性腸疾患（IBD）の推定有病率は240万人から310万人であり、人口統計によって影響にばらつきがあると報告しています。また、英国の出版社であるオックスフォード大学出版局によると、2023年には約322,600人のカナダ人が炎症性腸疾患（IBD）と共に生活していると推定されています。したがって、過敏性腸症候群（IBS）の有病率の増加が鎮痙薬市場の成長を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界鎮痙薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、制約）
• 最終用途産業の分析
• 世界の鎮痙薬市場：成長率分析
• 世界の鎮痙薬市場の実績：規模と成長, 2019-2024
• 世界の鎮痙薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界鎮痙薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の鎮痙薬市場薬物による、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジシクロミン塩酸塩
• ロペラミド塩酸塩
• その他の薬物
• 世界の鎮痙薬市場適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 過敏性腸症候群
• 胃の痛み
• その他の適応症
• 世界の鎮痙薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の管理方法
• 世界の鎮痙薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界の鎮痙薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界の鎮痙薬市場、ジシクロミン塩酸塩のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口錠剤
• 注射剤
• 世界の鎮痙薬市場、ロペラミド塩酸塩のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口錠剤
• 液体製剤
• 世界の鎮痙薬市場、その他の医薬品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヒオスシンブチル臭化物（スコポラミン）
• ペパーミントオイル
• アトロピン
• その他の抗けいれん薬

第7章 地域別・国別分析

• 世界の鎮痙薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の鎮痙薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 鎮痙薬市場：競合情勢
• 鎮痙薬市場：企業プロファイル
  • Daiichi Sankyo Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis
  • Hikma Pharmaceuticals plc Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Shanghai Fosun Pharmaceutical Co. Ltd.
• Takeda Pharmaceutical Company Limited
• Akorn Inc.
• Aurobindo Pharma Limited
• Lannett Company Inc.
• Nexus Pharmaceuticals Inc.
• Actiza Pharmaceutical Private Limited
• Blue Cross Laboratories Pvt. Ltd.
• Dr. Reddy's Laboratories Ltd.
• Lexicare Pharma Pvt. Ltd.
• Solitaire Pharmacia Private Limited
• Strides Pharma Science Limited
• Wellona Pharma Private Limited
• SunGen Pharma LLC
• GlaxoSmithKline plc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 鎮痙薬市場2029：新たな機会を提供する国
• 鎮痙薬市場2029：新たな機会を提供するセグメント
• 鎮痙薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Antispasmodic drugs are medications designed to treat, prevent, or decrease the frequency of muscular spasms, especially those involving smooth muscle, such as those occurring in the walls of the gastrointestinal tract. These drugs function by slowing down the normal movements of the gut and inducing relaxation in the muscles of the stomach and intestines.

Key drugs in the category of antispasmodics include dicyclomine hydrochloride, loperamide hydrochloride, and others. Dicyclomine is an anticholinergic medication that reduces spasms in the gastrointestinal muscles by inhibiting the activity of a natural chemical in the body. Indications for the use of antispasmodic drugs include conditions such as irritable bowel syndrome, stomach cramps, and others. These medications can be administered through oral, parenteral, and other modes. Distribution channels for antispasmodic drugs include hospital pharmacies, online pharmacies, and retail pharmacies, with end-users ranging from hospitals and homecare settings to specialty clinics and others.

The antispasmodics drugs market research report is one of a series of new reports from The Business Research Company that provides antispasmodics drugs market statistics, including antispasmodics drugs industry global market size, regional shares, competitors with antispasmodics drugs market share, detailed antispasmodics drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the antispasmodics drugs industry. This antispasmodic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antispasmodics drugs market size has grown strongly in recent years. It will grow from $13.76 billion in 2024 to $15.07 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to rising prevalence of spasmodic conditions, advancements in medical research, growing aging population, changing lifestyles, improvements in diagnosis.

The antispasmodics drugs market size is expected to see strong growth in the next few years. It will grow to $21.91 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to increasing healthcare expenditure, personalized medicine, global population growth, emerging markets, clinical trials and research. Major trends in the forecast period include expanding indications for antispasmodics, healthcare infrastructure development, advancements in drug development, increasing awareness and diagnosis, preference for non-invasive treatment options.

The anticipated rise in the elderly population stands as a driving force behind the growth of the antispasmodic drug market. Individuals aged 65 and above, often grappling with various physical and psychological health challenges, find relief in antispasmodic drugs to manage symptoms linked to conditions causing muscle spasms or cramping. These drugs also prove beneficial for ailments such as irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), interstitial cystitis, and uterine cramping. In October 2022, the World Health Organization (WHO) projected a substantial increase in the global population aged 60 and above, expected to reach 1.4 billion by 2030 and double to 2.1 billion by 2050. This demographic shift, including a significant rise in those aged 80 or older, estimated to reach 426 million by 2050, underscores the impetus driving the antispasmodic drug market linked to an expanding elderly populace.

The rising incidence of irritable bowel syndrome (IBS) is anticipated to drive the growth of the antispasmodics drugs market in the future. IBS is a prevalent digestive disorder characterized by a collection of symptoms affecting the large intestine (colon), causing discomfort and disrupting normal digestive function. Antispasmodic medications are utilized in the treatment of IBS to target and relieve muscle spasms and cramps in the gastrointestinal tract, providing relief from abdominal pain and discomfort for patients. For example, in June 2024, the Centers for Disease Control and Prevention (CDC), a US federal agency, reported that the estimated prevalence of inflammatory bowel disease (IBD) in the U.S. ranges from 2.4 to 3.1 million, with variations in impact among different demographics. Additionally, according to Oxford University Press, a UK publishing company, approximately 322,600 Canadians were estimated to be living with inflammatory bowel disease (IBD) in 2023. Therefore, the increasing prevalence of irritable bowel syndrome (IBS) is fueling the growth of the antispasmodics drugs market.

Innovative product developments emerge as a pivotal trend fueling the ascent of the antispasmodic drugs market. Key players in this domain prioritize pioneering solutions to fortify their market positions. For instance, in April 2022, Ardelyx Inc., a US-based biopharmaceutical company, unveiled IBSRELA, an NHE-3 inhibitor tailored for individuals grappling with irritable bowel syndrome with constipation (IBS-C). This product represents a breakthrough therapeutic option boasting a novel mode of action, yielding significant efficacy in addressing constipation and assorted abdominal symptoms prevalent in IBS-C patients, as substantiated by Phase 3 clinical studies. This innovative approach underscores the market's trend towards developing impactful solutions catering to specific conditions within the antispasmodic drugs segment.

Prominent entities within the antispasmodics drugs market are unveiling new products as part of their strategy to fortify their market presence. For example, in January 2023, Lupin Limited, an India-based pharmaceutical company, introduced Fesoterodine Fumarate, an FDA-approved generic antispasmodic drug. This medication is specifically designed to address certain bladder issues such as overactive bladder and neurogenic detrusor overactivity. Belonging to the antispasmodic drug class, Fesoterodine Fumarate functions by relaxing the muscles in the bladder. It is available in extended-release tablet form, representing a new addition to Lupin Limited's repertoire in addressing bladder-related ailments.

In October 2022, Silo Wellness Inc., a US-based company specializing in psychedelic therapy, concluded the acquisition of Dyscovry Science Ltd. for an undisclosed amount. This strategic acquisition enables Silo Wellness to consolidate its presence in the psychedelic business landscape. Dyscovry Science Ltd., a Canada-based biotechnology firm, specializes in biosynthetic production of psilocybin and its derivatives for treating irritable bowel syndrome. By incorporating Dyscovry Science Ltd., Silo Wellness aims to encompass both facets of the psychedelic industry, augmenting its capabilities in research and biosynthetic development for innovative treatment solutions.

Major companies operating in the antispasmodics drugs market include Daiichi Sankyo Company Limited, Fresenius Kabi AG, Hikma Pharmaceuticals plc, Johnson & Johnson Services Inc., Pfizer Inc., Shanghai Fosun Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Akorn Inc., Aurobindo Pharma Limited, Lannett Company Inc., Nexus Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Blue Cross Laboratories Pvt. Ltd., Dr. Reddy's Laboratories Ltd., Lexicare Pharma Pvt. Ltd., Solitaire Pharmacia Private Limited, Strides Pharma Science Limited, Wellona Pharma Private Limited, SunGen Pharma LLC, GlaxoSmithKline plc, Novartis AG, Sanofi SA, AstraZeneca plc, Merck & Co. Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Endo Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Lupin Ltd.

North America was the largest region in the antispasmodics drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the antispasmodics drugs market report during the forecast period. The regions covered in the antispasmodics drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the antispasmodics drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antispasmodics drugs market consists of sales of natural alkaloids such as atropine, belladonna, hyoscyamine, scopolamine, and related drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antispasmodics Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antispasmodics drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antispasmodics drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antispasmodics drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug: Dicyclomine Hydrochloride; Loperamide Hydrochloride; Other Drugs
• 2) By Indication: Irritable Bowel Syndrome; Stomach Cramps; Other Indications
• 3) By Route Of Administration: Oral; Parenteral; Other Modes Of Administrations
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 5) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Dicyclomine Hydrochloride: Oral Tablets; Injectable Formulations
• 2) By Loperamide Hydrochloride: Oral Tablets; Liquid Formulations
• 3) By Other Drugs: Hyoscine Butylbromide (Scopolamine); Peppermint Oil; Atropine; Other Antispasmodics
• Companies Mentioned: Daiichi Sankyo Company Limited; Fresenius Kabi AG; Hikma Pharmaceuticals plc; Johnson & Johnson Services Inc.; Pfizer Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Antispasmodics Drugs Market Characteristics

3. Antispasmodics Drugs Market Trends And Strategies

4. Antispasmodics Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Antispasmodics Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Antispasmodics Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Antispasmodics Drugs Market Growth Rate Analysis
• 5.4. Global Antispasmodics Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Antispasmodics Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Antispasmodics Drugs Total Addressable Market (TAM)

6. Antispasmodics Drugs Market Segmentation

• 6.1. Global Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dicyclomine Hydrochloride
• Loperamide Hydrochloride
• Other Drugs
• 6.2. Global Antispasmodics Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Irritable Bowel Syndrome
• Stomach Cramps
• Other Indications
• 6.3. Global Antispasmodics Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Modes Of Administrations
• 6.4. Global Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmnacy
• 6.5. Global Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End-Users
• 6.6. Global Antispasmodics Drugs Market, Sub-Segmentation Of Dicyclomine Hydrochloride, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Tablets
• Injectable Formulations
• 6.7. Global Antispasmodics Drugs Market, Sub-Segmentation Of Loperamide Hydrochloride, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Tablets
• Liquid Formulations
• 6.8. Global Antispasmodics Drugs Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hyoscine Butylbromide (Scopolamine)
• Peppermint Oil
• Atropine
• Other Antispasmodics

7. Antispasmodics Drugs Market Regional And Country Analysis

• 7.1. Global Antispasmodics Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Antispasmodics Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Antispasmodics Drugs Market

• 8.1. Asia-Pacific Antispasmodics Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Antispasmodics Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Antispasmodics Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Antispasmodics Drugs Market

• 9.1. China Antispasmodics Drugs Market Overview
• 9.2. China Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Antispasmodics Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Antispasmodics Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Antispasmodics Drugs Market

• 10.1. India Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Antispasmodics Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Antispasmodics Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Antispasmodics Drugs Market

• 11.1. Japan Antispasmodics Drugs Market Overview
• 11.2. Japan Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Antispasmodics Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Antispasmodics Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Antispasmodics Drugs Market

• 12.1. Australia Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Antispasmodics Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Antispasmodics Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Antispasmodics Drugs Market

• 13.1. Indonesia Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Antispasmodics Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Antispasmodics Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Antispasmodics Drugs Market

• 14.1. South Korea Antispasmodics Drugs Market Overview
• 14.2. South Korea Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Antispasmodics Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Antispasmodics Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Antispasmodics Drugs Market

• 15.1. Western Europe Antispasmodics Drugs Market Overview
• 15.2. Western Europe Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Antispasmodics Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Antispasmodics Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Antispasmodics Drugs Market

• 16.1. UK Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Antispasmodics Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Antispasmodics Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Antispasmodics Drugs Market

• 17.1. Germany Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Antispasmodics Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Antispasmodics Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Antispasmodics Drugs Market

• 18.1. France Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Antispasmodics Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Antispasmodics Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Antispasmodics Drugs Market

• 19.1. Italy Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Antispasmodics Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Antispasmodics Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Antispasmodics Drugs Market

• 20.1. Spain Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Antispasmodics Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Antispasmodics Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Antispasmodics Drugs Market

• 21.1. Eastern Europe Antispasmodics Drugs Market Overview
• 21.2. Eastern Europe Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Antispasmodics Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Antispasmodics Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Antispasmodics Drugs Market

• 22.1. Russia Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Antispasmodics Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Antispasmodics Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Antispasmodics Drugs Market

• 23.1. North America Antispasmodics Drugs Market Overview
• 23.2. North America Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Antispasmodics Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Antispasmodics Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Antispasmodics Drugs Market

• 24.1. USA Antispasmodics Drugs Market Overview
• 24.2. USA Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Antispasmodics Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Antispasmodics Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Antispasmodics Drugs Market

• 25.1. Canada Antispasmodics Drugs Market Overview
• 25.2. Canada Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Antispasmodics Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Antispasmodics Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Antispasmodics Drugs Market

• 26.1. South America Antispasmodics Drugs Market Overview
• 26.2. South America Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Antispasmodics Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Antispasmodics Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Antispasmodics Drugs Market

• 27.1. Brazil Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Antispasmodics Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Antispasmodics Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Antispasmodics Drugs Market

• 28.1. Middle East Antispasmodics Drugs Market Overview
• 28.2. Middle East Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Antispasmodics Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Antispasmodics Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Antispasmodics Drugs Market

• 29.1. Africa Antispasmodics Drugs Market Overview
• 29.2. Africa Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Antispasmodics Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Antispasmodics Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Antispasmodics Drugs Market Competitive Landscape And Company Profiles

• 30.1. Antispasmodics Drugs Market Competitive Landscape
• 30.2. Antispasmodics Drugs Market Company Profiles
  • 30.2.1. Daiichi Sankyo Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Hikma Pharmaceuticals plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Antispasmodics Drugs Market Other Major And Innovative Companies

• 31.1. Shanghai Fosun Pharmaceutical Co. Ltd.
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Akorn Inc.
• 31.4. Aurobindo Pharma Limited
• 31.5. Lannett Company Inc.
• 31.6. Nexus Pharmaceuticals Inc.
• 31.7. Actiza Pharmaceutical Private Limited
• 31.8. Blue Cross Laboratories Pvt. Ltd.
• 31.9. Dr. Reddy's Laboratories Ltd.
• 31.10. Lexicare Pharma Pvt. Ltd.
• 31.11. Solitaire Pharmacia Private Limited
• 31.12. Strides Pharma Science Limited
• 31.13. Wellona Pharma Private Limited
• 31.14. SunGen Pharma LLC
• 31.15. GlaxoSmithKline plc

32. Global Antispasmodics Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antispasmodics Drugs Market

34. Recent Developments In The Antispasmodics Drugs Market

35. Antispasmodics Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Antispasmodics Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Antispasmodics Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Antispasmodics Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer